210 related articles for article (PubMed ID: 38123987)
21. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
Hata C; Nakaoka H; Xiang Y; Wang D; Yang A; Liu D; Liu F; Zou Q; Wei L; Zheng K; Inoue I; You H
J Hum Genet; 2020 Jul; 65(7):577-587. PubMed ID: 32029870
[TBL] [Abstract][Full Text] [Related]
22. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
[TBL] [Abstract][Full Text] [Related]
23. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
24. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer.
Hauke J; Horvath J; Groß E; Gehrig A; Honisch E; Hackmann K; Schmidt G; Arnold N; Faust U; Sutter C; Hentschel J; Wang-Gohrke S; Smogavec M; Weber BHF; Weber-Lassalle N; Weber-Lassalle K; Borde J; Ernst C; Altmüller J; Volk AE; Thiele H; Hübbel V; Nürnberg P; Keupp K; Versmold B; Pohl E; Kubisch C; Grill S; Paul V; Herold N; Lichey N; Rhiem K; Ditsch N; Ruckert C; Wappenschmidt B; Auber B; Rump A; Niederacher D; Haaf T; Ramser J; Dworniczak B; Engel C; Meindl A; Schmutzler RK; Hahnen E
Cancer Med; 2018 Apr; 7(4):1349-1358. PubMed ID: 29522266
[TBL] [Abstract][Full Text] [Related]
25. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
26. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
[TBL] [Abstract][Full Text] [Related]
27. Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series.
Sukumar J; Kassem M; Agnese D; Pilarski R; Ramaswamy B; Sweet K; Sardesai S
Breast Cancer Res Treat; 2021 Apr; 186(2):569-575. PubMed ID: 33507482
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study.
Cheng HF; Tsai YF; Liu CY; Hsu CY; Lien PJ; Lin YS; Chao TC; Lai JI; Feng CJ; Chen YJ; Chen BF; Chiu JH; Tseng LM; Huang CC
Breast Cancer Res; 2023 Dec; 25(1):152. PubMed ID: 38098088
[TBL] [Abstract][Full Text] [Related]
29. Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Katz SJ
JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33426465
[TBL] [Abstract][Full Text] [Related]
30. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
Nones K; Johnson J; Newell F; Patch AM; Thorne H; Kazakoff SH; de Luca XM; Parsons MT; Ferguson K; Reid LE; McCart Reed AE; Srihari S; Lakis V; Davidson AL; Mukhopadhyay P; Holmes O; Xu Q; Wood S; Leonard C; ; ; ; Beesley J; Harris JM; Barnes D; Degasperi A; Ragan MA; Spurdle AB; Khanna KK; Lakhani SR; Pearson JV; Nik-Zainal S; Chenevix-Trench G; Waddell N; Simpson PT
Ann Oncol; 2019 Jul; 30(7):1071-1079. PubMed ID: 31090900
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
[TBL] [Abstract][Full Text] [Related]
32. New germline mutations in BRCA1, ATM, MUTYH, and RAD51D genes in Tuvans early-onset breast cancer patients.
Gervas P; Molokov A; Ivanova A; Panferova Y; Kiselev A; Chernyshova A; Pisareva L; Choynzonov E; Cherdyntseva N
Exp Oncol; 2021 Mar; 43(1):52-55. PubMed ID: 33785725
[TBL] [Abstract][Full Text] [Related]
33. Mutation status of RAD51C, PALB2 and BRIP1 in 100 Japanese familial breast cancer cases without BRCA1 and BRCA2 mutations.
Sato K; Koyasu M; Nomura S; Sato Y; Kita M; Ashihara Y; Adachi Y; Ohno S; Iwase T; Kitagawa D; Nakashima E; Yoshida R; Miki Y; Arai M
Cancer Sci; 2017 Nov; 108(11):2287-2294. PubMed ID: 28796317
[TBL] [Abstract][Full Text] [Related]
34. High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer.
Evans DG; van Veen EM; Byers HJ; Evans SJ; Burghel GJ; Woodward ER; Harkness EF; Eccles DM; Greville-Haygate SL; Ellingford JM; Bowers NL; Pereira M; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
J Med Genet; 2022 Feb; 59(2):115-121. PubMed ID: 33758026
[TBL] [Abstract][Full Text] [Related]
35. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
[TBL] [Abstract][Full Text] [Related]
36. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
[TBL] [Abstract][Full Text] [Related]
37. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
[TBL] [Abstract][Full Text] [Related]
38. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
[TBL] [Abstract][Full Text] [Related]
39. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.
Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J
Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015
[TBL] [Abstract][Full Text] [Related]
40. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study.
Reiner AS; Sisti J; John EM; Lynch CF; Brooks JD; Mellemkjær L; Boice JD; Knight JA; Concannon P; Capanu M; Tischkowitz M; Robson M; Liang X; Woods M; Conti DV; Duggan D; Shore R; Stram DO; Thomas DC; Malone KE; Bernstein L; ; Bernstein JL
J Clin Oncol; 2018 May; 36(15):1513-1520. PubMed ID: 29620998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]